Factors Driving PDT LED Light Therapy Machine Prices in 2025: A Market Overview

WEIFANG, SHANDONG, CHINA, January 21, 2026 /EINPresswire.com/ -- 1. Rising Global Demand for PDT LED Light Therapy As ...

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansionData to complement previously announced ...
CURE

FDA Accepts Filing of Ameluz for Superficial Basal Cell Carcinoma

The FDA has accepted a sNDA for Ameluz topical gel, used in combination with the RhodoLED red-light lamp series, for superficial basal cell carcinoma treatment.
The Manila Times

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz® vs. vehicle gel ...
Seeking Alpha

Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk

WOBURN, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the ...
Medical Dialogues

Phase 3 Evidence Supports Ameluz Photodynamic Therapy for Actinic Keratosis

Phase 3 clinical trial results demonstrate that Ameluz photodynamic therapy is an effective treatment for actinic keratoses ...
The American Journal of Managed Care

Patients With Actinic Keratosis Prefer Simulated Daylight PDT Over More Painful Red Light PDT

A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient ...

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first and only PDT ...
National Institute for Health and Care Excellence

Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions)

Basal cell carcinoma is the most common form of skin cancer. It is generally a slow-growing, locally invasive epidermal skin tumour that rarely spreads to other distant parts of the body. Although it ...